| 1479 |
National Cancer Institute |
Html |
en |
Prostate Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of prostate cancer. |
| prostate cancer warrants | 0.499797 |
| screen-detected prostate cancer | 0.525488 |
| grade prostate cancer | 0.523426 |
| Low-Risk Prostate Cancer | 0.500547 |
| Engl J Med | 0.559367 |
| advanced prostate cancer | 0.529012 |
| prostate cancer treatment | 0.512803 |
| Prostate Cancer Prostatic | 0.498893 |
| clinically localized prostate | 0.673086 |
| Int J Radiat | 0.493888 |
| metastatic prostate cancer | 0.500485 |
| Radiat Oncol Biol | 0.568418 |
| prostate cancer increases | 0.499539 |
| prostate specific antigen | 0.536475 |
| Natl Cancer Inst | 0.689089 |
| organ-confined prostate cancer | 0.499295 |
| radiation therapy | 0.50488 |
| Prostate cancer diagnosis | 0.525315 |
| prostate carcinoma | 0.533902 |
| et al. | 0.579019 |
| nonpalpable prostate cancer | 0.508262 |
| National Prostate Cancer | 0.512122 |
| Prostate Cancer section | 0.509753 |
| Prostate Cancer Outcomes | 0.519033 |
| recurrent prostate cancer | 0.502138 |
|
| castration-resistant prostate cancer | 0.500277 |
| prostate cancer eligible | 0.506835 |
| Prostate Cancer Intervention | 0.504501 |
| Prostate cancer radiation | 0.50507 |
| PUBMED Abstract | 0.502954 |
| radical prostatectomy | 0.797797 |
| Localized Prostate Cancer | 0.557914 |
| early prostate cancer | 0.559358 |
| Castration-Sensitive Prostate Cancer | 0.498217 |
| low grade prostate | 0.495809 |
| localised prostate cancer | 0.501262 |
| radical retropubic prostatectomy | 0.495282 |
| Abstract | 0.672665 |
| Clin Oncol | 0.580989 |
| Oncol Biol Phys | 0.571819 |
| prostate cancer prognosis | 0.512411 |
| Prostate Cancer Register | 0.511523 |
| prostate cancer survival | 0.523146 |
| risk prostate cancer | 0.510212 |
| prostate cancer | 0.923001 |
| Association Prostate Cancer | 0.506382 |
| prostate cancer progression | 0.524034 |
| prostate cancer recurrence | 0.538252 |
| watchful waiting | 0.496685 |
|
CLICK HERE |
| 1531 |
National Cancer Institute |
Html |
en |
Childhood Ependymoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood ependymoma. |
| cancer treatment | 0.626698 |
| recurrent childhood ependymoma | 0.554401 |
| following PDQ summaries | 0.501476 |
| PDQ cancer information | 0.603175 |
| high-grade cancer cells | 0.52438 |
| clinical trial search | 0.497636 |
| brain tumors | 0.624619 |
| Childhood Ependymoma Treatment | 0.537776 |
| clinical trials | 0.997686 |
| Pediatric Treatment Editorial | 0.517454 |
| cancer information summary | 0.560017 |
| clinical trial | 0.708531 |
| anaplastic ependymoma | 0.508455 |
| patients | 0.511213 |
| NCI PDQ cancer | 0.514722 |
| brain stem | 0.532471 |
| radiation therapy | 0.873758 |
| Treatment Editorial Board | 0.522486 |
| treatment | 0.865472 |
| magnetic resonance imaging | 0.501265 |
| childhood ependymoma | 0.915073 |
| cancer cells | 0.900504 |
| standard treatment | 0.509266 |
| Cancer Information Service | 0.497532 |
| intensity-modulated radiation therapy | 0.526143 |
|
| PDQ Pediatric Treatment | 0.501585 |
| Conformal radiation therapy | 0.512713 |
| myxopapillary ependymoma | 0.509213 |
| treatment clinical trials | 0.542772 |
| National Cancer Institute | 0.559542 |
| spinal cord | 0.912544 |
| tumor cells | 0.497383 |
| effects cancer treatment | 0.524938 |
| proton-beam radiation therapy | 0.524248 |
| new treatment | 0.578083 |
| ependymoma forms | 0.516544 |
| childhood cancer information | 0.507379 |
| childhood brain tumors | 0.536709 |
| external radiation therapy | 0.570552 |
| treatment clinical trial | 0.51013 |
| brain | 0.714551 |
| PDQ summary | 0.496378 |
| RELA fusion–positive ependymoma | 0.556789 |
| cancer clinical trials | 0.531786 |
| tumor | 0.709426 |
| treatment options | 0.516335 |
| cancer information summaries | 0.496292 |
| comprehensive cancer information | 0.49561 |
| cancer | 0.953861 |
|
CLICK HERE |
| 1629 |
National Cancer Institute |
Html |
en |
Penile Cancer Treatment (PDQ®)–Patient Version |
Penile cancer is highly curable when found early. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for penile cancer. |
| cancer treatment | 0.320382 |
| biologic therapy | 0.30297 |
| Lymph node dissection | 0.308565 |
| tissue | 0.393322 |
| erectile tissue | 0.338087 |
| body | 0.324795 |
| PDQ cancer information | 0.34528 |
| clinical trial search | 0.382837 |
| Penile Cancer Treatment | 0.305192 |
| clinical trials | 0.721694 |
| cancer information summary | 0.319238 |
| clinical trial | 0.569243 |
| Recurrent penile cancer | 0.32422 |
| patients | 0.29378 |
| lymph node biopsy | 0.446032 |
| blood vessels | 0.32868 |
| sentinel lymph node | 0.563667 |
| spongy tissue | 0.289271 |
| treatment clinical trial | 0.276059 |
| NCI PDQ cancer | 0.28258 |
| lymph nodes | 0.475166 |
| radiation therapy | 0.416871 |
| General information | 0.303882 |
| general cancer information | 0.275537 |
| treatment | 0.454305 |
|
| wide local excision | 0.318281 |
| tumor cells | 0.306254 |
| new cancer treatments | 0.275369 |
| NCI-supported cancer | 0.316489 |
| cancer cells | 0.48036 |
| Cancer Information Service | 0.276468 |
| penile cancer | 0.671625 |
| connective tissue | 0.347145 |
| treatment clinical trials | 0.301804 |
| National Cancer Institute | 0.364819 |
| penis | 0.345276 |
| lymph vessels | 0.289266 |
| new treatment | 0.324645 |
| metastatic penile cancer | 0.30082 |
| cancer clinical trials | 0.389935 |
| stage | 0.320852 |
| tumor | 0.326492 |
| cancer information summaries | 0.27434 |
| comprehensive cancer information | 0.27491 |
| internal radiation therapy | 0.325191 |
| cancer | 0.921282 |
| information | 0.35457 |
| lymph ducts | 0.299322 |
| standard treatment | 0.273177 |
|
CLICK HERE |
| 1856 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de nasofaringe (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de nasofaringe. |
| recurrent nasopharyngeal carcinoma | 0.314884 |
| locoregionally advanced | 0.32749 |
| T-stage nasopharyngeal carcinoma | 0.309795 |
| advanced nasopharyngeal carcinoma | 0.746023 |
| nasopharyngeal cancer | 0.331855 |
| concurrent chemoradiotherapy | 0.311059 |
| advanced squamous | 0.313322 |
| randomized study | 0.31172 |
| Radiat Oncol Biol | 0.67282 |
| DeVita VT Jr | 0.315434 |
| randomized trial | 0.419327 |
| concurrent-adjuvant chemotherapy | 0.32145 |
| chemotherapy with radiotherapy | 0.314748 |
| Natl Cancer Inst | 0.315479 |
| randomized trial comparing | 0.314639 |
| treated with radiotherapy | 0.309308 |
| undifferentiated nasopharyngeal carcinoma | 0.317213 |
| patients with | 0.383207 |
| metastatic nasopharyngeal carcinoma | 0.31503 |
| radiation therapy | 0.346053 |
| carcinoma treated with | 0.317616 |
| with radiotherapy | 0.334247 |
| Tung SY | 0.313347 |
| Teo PM | 0.315435 |
| preliminary results | 0.31387 |
|
| eight randomized trials | 0.309618 |
| radiotherapy with | 0.310444 |
| nasopharyngeal carcinoma patients | 0.31096 |
| prospective randomized | 0.316414 |
| advanced undifferentiated carcinoma | 0.309346 |
| nasopharyngeal carcinoma | 0.974941 |
| Chan AT | 0.318151 |
| chemotherapy vs radiotherapy | 0.31098 |
| adjuvant chemotherapy with | 0.312314 |
| local control | 0.310914 |
| Clin Oncol | 0.499014 |
| Werning JW | 0.309232 |
| Oncol Biol Phys | 0.70745 |
| locally-advanced nasopharyngeal carcinoma | 0.317916 |
| primary nasopharyngeal carcinoma | 0.309776 |
| neck cancer | 0.35727 |
| American Joint Committee | 0.310074 |
| with or without | 0.33621 |
| locally advanced | 0.381657 |
| T2 nasopharyngeal carcinoma | 0.309762 |
| nasopharyngeal carcinoma treated | 0.317452 |
| node-positive nasopharyngeal carcinoma | 0.317088 |
| Cancer Study Group | 0.311102 |
| induction chemotherapy | 0.311013 |
|
CLICK HERE |
| 1882 |
National Cancer Institute |
Html |
es |
Tratamiento del ependimoma infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil. |
| Hielscher T | 0.367784 |
| Grado III | 0.497368 |
| prognostic factors | 0.418199 |
| Merchant TE | 0.351136 |
| Brain Tumor Registry | 0.358501 |
| Korshunov A | 0.366815 |
| spinal cord ependymomas | 0.397087 |
| posterior fossa ependymoma | 0.679456 |
| C11orf95-RELA fusions drive | 0.339744 |
| lÃquido cefalorraquÃdeo | 0.413022 |
| infratentorial childhood ependymomas | 0.36981 |
| localized ependymoma | 0.366693 |
| Radiat Oncol Biol | 0.730863 |
| gen rela | 0.348774 |
| Pediatric Brain Tumor | 0.377851 |
| central nervous system | 0.408683 |
| patients with | 0.480087 |
| paediatric ependymoma | 0.378048 |
| pediatric intracranial ependymoma | 0.417211 |
| Acta Neuropathol | 0.362477 |
| Mack SC | 0.397938 |
| Retrospective Multicohort Analysis | 0.345199 |
| cuarto ventrÃculo | 0.34367 |
| United States | 0.381387 |
| childhood ependymoma | 0.440498 |
|
| intracranial ependymoma | 0.9229 |
| Neuro Oncol | 0.422395 |
| pediatric patients with | 0.359423 |
| radioterapia posoperatoria | 0.479259 |
| Pediatr Blood Cancer | 0.435451 |
| myxopapillary ependymoma | 0.400108 |
| spinal cord | 0.397509 |
| supratentorial ependymoma | 0.360521 |
| C11orf95-RELA fusions | 0.341174 |
| ependymoma patients with | 0.34014 |
| infantil recién | 0.356568 |
| Clin Oncol | 0.43496 |
| childhood intracranial ependymoma | 0.4276 |
| sistema nervioso central | 0.476331 |
| with intracranial ependymoma | 0.449085 |
| Oncol Biol Phys | 0.751374 |
| brain tumor | 0.436772 |
| Witt H | 0.430118 |
| Grado II | 0.78433 |
| patients with localized | 0.344179 |
| Central Brain Tumor | 0.357242 |
| ependimoma infantil grupo | 0.387504 |
| Childs Nerv Syst | 0.378828 |
| Brain Tumor Consortium | 0.35913 |
|
CLICK HERE |
| 1936 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extracraneales de células germinativas en la niñez (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extracraneales de células germinativas en la niñez. |
| siguientes procedimientos | 0.383487 |
| células madre | 0.843271 |
| posibles factores | 0.316699 |
| estadio iv | 0.881585 |
| adultos jóvenes | 0.38604 |
| siguientes áreas | 0.332444 |
| afecciones quizás | 0.318252 |
| Diferentes tipos | 0.319717 |
| Estadio IIIC | 0.352194 |
| siguientes tipos | 0.320718 |
| tumores mixtos | 0.42367 |
| rayos x | 0.344377 |
| estadio ib | 0.390154 |
| niño ayuda | 0.314653 |
| efectos tardÃos | 0.453508 |
| PDQ Efectos tardÃos | 0.33586 |
| teratomas benignos | 0.329972 |
| cm).estadio iiia | 0.314756 |
| tarde.ampliar ecografÃa | 0.317174 |
| National Cancer Institute | 0.311618 |
| tumores benignos | 0.431931 |
| IRMN).Ampliar Imágenes | 0.3138 |
| estadio iic.estadio iia | 0.359243 |
| siguientes lugares | 0.327905 |
|
| germinomas.Los disgerminomas | 0.320088 |
| siguientes riesgos | 0.31126 |
| tratamiento quizás | 0.335386 |
| Instituto Nacional | 0.320237 |
| PDQ Tratamiento | 0.64104 |
| células germinativas.Teratomas | 0.463139 |
| estadio iiia | 0.352727 |
| efectos tardÃos quizás | 0.32327 |
| células germinativas mixtos | 0.491909 |
| siguientes marcadores | 0.329439 |
| siguientes signos | 0.328509 |
| nuevos tipos | 0.313861 |
| saco vitelino | 0.360548 |
| partes distantes | 0.338927 |
| coriónica humana beta | 0.527277 |
| Physician Data Query | 0.340834 |
| sistema nervioso central | 0.331507 |
| estadio iii | 0.993051 |
| germinomas.Los tumores | 0.426016 |
| tumoresde células | 0.36494 |
| estadio ic.estadio ia | 0.359207 |
| siguientes pruebas | 0.327352 |
| marcadores tumorales.La | 0.319745 |
|
CLICK HERE |
| 1966 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de labio y de cavidad oral (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de labio y de cavidad oral. |
| medicamentos retinoides | 0.568081 |
| siguientes procedimientos | 0.97932 |
| siguientes elementos | 0.624752 |
| estadio ii | 0.723086 |
| rayos x | 0.572217 |
| pequeñas marcas | 0.537003 |
| estadio ivc | 0.583451 |
| necesarios implantes | 0.546577 |
| siguientes riesgos | 0.500736 |
| malla ayuda | 0.53799 |
| Instituto Nacional | 0.536147 |
| área pequeña detrás | 0.642422 |
| presente sección | 0.536306 |
|
| partes distantes | 0.555475 |
| Physician Data Query | 0.531283 |
| estadio iii | 0.581263 |
| libre uso | 0.500877 |
| radioterapia hiperfraccionada | 0.899395 |
| cáncer.ampliar radioterapia | 0.670655 |
| Cancer Institute | 0.499502 |
| siguientes enlaces | 0.516515 |
| siguientes pruebas | 0.617318 |
| Dientes flojos | 0.587562 |
| pequeño espejo | 0.576408 |
| siguientes estadios | 0.58645 |
|
CLICK HERE |
| 3433 |
National Cancer Institute |
Html |
es |
Plantas crucíferas y la prevención del cáncer |
Hoja informativa que resume los resultados de estudios sobre las plantas crucíferas y el cáncer. Incluye una lista de plantas crucíferas y las guías alimenticias recomendadas para el consumo de verduras.
|
| lung-cancer risk | 0.307792 |
| vegetable consumption | 0.312833 |
| Mehta RG | 0.302691 |
| risk only | 0.307938 |
| Breast Cancer Detection | 0.318522 |
| Crowley-Nowick P | 0.30257 |
| P1 polymorphisms | 0.302724 |
| from case-control studies | 0.304583 |
| Appleby P | 0.302596 |
| vitaminas c | 0.302699 |
| Estados Unidos | 0.329183 |
| American Journal | 0.315502 |
| enzima glutatión | 0.302759 |
| phytochemicals derived from | 0.304521 |
| PubMed Abstract | 0.825953 |
| Verhoeven DT | 0.30258 |
| Eggleston IM | 0.302576 |
| Drug Metabolism Reviews | 0.304253 |
| International Journal | 0.303618 |
| investigation into cancer | 0.31721 |
| cohort study | 0.390686 |
| Health Professionals | 0.302655 |
| S-transferase M1 | 0.306619 |
| multiethnic case-control study | 0.310202 |
| plantas crucÃferas | 0.972584 |
|
| PaÃses Bajos | 0.321735 |
| mayores cantidades | 0.306865 |
| alto consumo | 0.304048 |
| Project follow-up cohort | 0.305167 |
| Multiethnic Cohort Study | 0.310843 |
| sustancias llamadas glucosinolatos | 0.304891 |
| among men | 0.30319 |
| Murillo G | 0.302582 |
| prospective cohort study | 0.312078 |
| lower lung | 0.303353 |
| fruit consumption | 0.320125 |
| Clinical Nutrition | 0.310798 |
| rectal cancer | 0.307152 |
| Ziegler RG | 0.302564 |
| breast cancer | 0.357017 |
| Goldbohm RA | 0.316028 |
| Cancer Institute | 0.343115 |
| género brassica | 0.30299 |
| prospective study | 0.373394 |
| Bajos—el Netherlands Cohort | 0.307492 |
| glutathione s-transferase | 0.312115 |
| vegetable intakes | 0.305276 |
| Netherlands Cohort Study | 0.345768 |
| glutathione s-transferase polymorphisms | 0.30497 |
|
CLICK HERE |
| 3600 |
National Cancer Institute |
Html |
en |
NCI-COG Pediatric MATCH |
In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have certain genetic mutations will be treated with drugs that are matched to those mutations. |
| histiocytoses—whose cancer | 0.377277 |
| genetic makeup | 0.401588 |
| university medical centers | 0.467884 |
| brain tumors | 0.440585 |
| blood sample | 0.480719 |
| clinical trials | 0.534239 |
| additional genetic testing | 0.511528 |
| patients | 0.666156 |
| new treatment arms | 0.480309 |
| visit NCI | 0.372109 |
| solid tumors | 0.469802 |
| open treatment arms | 0.478804 |
| tumor sample | 0.358797 |
| Children’s Oncology | 0.616646 |
| genomic sequencing | 0.508758 |
| pediatric oncologist | 0.373126 |
| genetic changes | 0.973154 |
| precision medicine | 0.370826 |
| Hereditary genetic changes | 0.524899 |
| certain drugs | 0.381989 |
| screening step | 0.630676 |
| laboratory method | 0.368599 |
| Pediatric MATCH | 0.671874 |
| NCI-COG Pediatric MATCH | 0.543169 |
| specific targeted drugs | 0.540831 |
|
| nationwide cancer treatment | 0.58381 |
| cancer cells | 0.393101 |
| Cancer Information Service | 0.476816 |
| pediatric patients | 0.406357 |
| genetic counseling | 0.384583 |
| Clinical Trials Network | 0.452506 |
| enrollment steps | 0.358937 |
| treatment arm | 0.797992 |
| pediatric cancers | 0.526249 |
| experimental drugs | 0.379128 |
| genetic change | 0.798918 |
| study drugs | 0.381585 |
| contact NCI | 0.380025 |
| health insurance plans | 0.447587 |
| specific genetic changes | 0.498204 |
| experimental treatment | 0.509457 |
| certain genetic changes | 0.509656 |
| cancer centers | 0.372633 |
| cancer site | 0.501146 |
| clinical trials search | 0.454345 |
| tumors | 0.675099 |
| cancer information specialists | 0.479605 |
| Oncology Group | 0.642399 |
| standard treatment | 0.375977 |
|
CLICK HERE |
| 17222 |
National Cancer Institute |
Html |
en |
Tumor DNA Sequencing in Cancer Treatment |
Tumor DNA sequencing (also called genetic profiling or genetic testing) is a test to identify DNA changes in a patient’s cancer. In some cases, this information can help determine a treatment plan. |
| unique DNA changes | 0.327494 |
| health care provider | 0.21495 |
| lung tumor | 0.253938 |
| tumor sequencing | 0.343527 |
| specific genetic alterations | 0.302101 |
| healthy cells | 0.230873 |
| Multigene panel tests | 0.208409 |
| health care team | 0.2107 |
| frequently used sequencing | 0.320207 |
| hereditary cancer syndromes | 0.221971 |
| health care providers | 0.211937 |
| whole-genome sequencing | 0.314537 |
| cancer types | 0.228448 |
| DNA changes | 0.331071 |
| patient care | 0.205253 |
| targeted sequencing tests | 0.342426 |
| broad tumor DNA | 0.375946 |
| heterogeneous tumor | 0.233471 |
| DNA sequencing tests | 0.507176 |
| precision medicine | 0.222532 |
| single cancer type | 0.228039 |
| lung cancer cells | 0.3596 |
| treatment | 0.286045 |
| precision medicine trials | 0.205063 |
|
| DNA alteration | 0.251455 |
| NCI-COG Pediatric MATCH | 0.207207 |
| inherited genetic alteration | 0.228682 |
| DNA sequence | 0.253453 |
| cancer cells | 0.454035 |
| unique genetic alterations | 0.280668 |
| sequencing tests cost | 0.308627 |
| EGFR mutation | 0.209321 |
| Broad DNA sequencing | 0.411749 |
| cancer-causing DNA changes | 0.297683 |
| way cells function | 0.250384 |
| tumor dna | 0.91525 |
| tumor dna sequencing | 0.748819 |
| DNAÂ sequencer | 0.254089 |
| Clinical tumor DNA | 0.406068 |
| health care | 0.275099 |
| DNA sequencing test | 0.405098 |
| mRNA expression test | 0.209986 |
| breast cancer | 0.203535 |
| genetic alterations | 0.703142 |
| cancer | 0.512553 |
| standard treatment | 0.204466 |
| whole-exome sequencing | 0.314247 |
| quantitative mRNA test | 0.208612 |
|
CLICK HERE |